← Home

NEU

Healthcare & BiotechNEUTRAL

$20.510

as of 2026-09-09

5d return

+2.8%

20d return

-12.0%

60d return

+57.9%

RSI 14

30.7

vs 52w high

-13.2%

vs 52w low

+81.8%

SMA 20

Below

SMA 50

Above

Price · Volume · Broker flow
Markers = announcements (red triangle = price-sensitive). Volume amber = ≥2× ADV spike.
Loading chart…
Closest correlates
Pearson r on log returns, window: 82d
  • EMTr=0.72, window: 82d
  • PNTr=0.52, window: 82d
  • TM1r=0.41, window: 82d
  • WAUr=0.32, window: 82d
  • RMLr=0.31, window: 82d
Announcements — last 30 days
  • 2026-09-02Corporate Presentation, 2 September 2026
  • 2026-08-26PSmre_updateHalf Yearly Report and Accounts

    NEU's H1 2026 shows resilient 8% revenue growth and 29% USD-denominated royalty uplift from Acadia's DAYBUE, but NPAT fell 68% YoY due to R&D acceleration (Koala Phase 3 trial) offsetting higher royalties; debut dividend indicator (15c fully franked) and modest buyback ($3.9m vs $39.6m prior year) suggest confidence in sustained royalty streams but willingness to invest in pipeline.

  • 2026-08-25PSotherEuropean Commission grants marketing authorisation for DAYBU

    DAYBU becomes first and only approved treatment for Rett syndrome across 30 EU territories, unlocking $35m upfront and up to $170m in tiered milestones plus royalties through partner Acadia. This is a material regulatory de-risking event that validates trofinetide's commercial potential outside the US, though NEU is dependent on Acadia's execution and EU reimbursement dynamics.